Navigation Links
Neurologix Announces Second Quarter 2011 Financial Results
Date:8/11/2011

f operations after October 31, 2011 and to repay the promissory notes issued in December 2010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations.  The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information about factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2010 Annual Report on Form 10-K. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results. Further, the Company undertakes no obligation to update forward-looking statements after the date they are made or to conform the statements to actual results or changes in the Company's expectations.

    Contact:Neurologix
    Marc Panoff, 201-592-6451
    Chief Financial Officer
    marcpanoff@neurologix.net'/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
    2. Bion Announces New U.S. Patent for Phosphorus Removal
    3. ViaCyte Announces Executive Management Changes
    4. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
    5. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
    6. Osteologix Announces Completion of Corporate Consolidation
    7. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
    8. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
    9. Rigel Announces Second Quarter 2011 Financial Results
    10. WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc.
    11. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
    (Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
    (Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
    (Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
    Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
    ... , , CHICAGO, Sept. 17 ... risk management services, insurance and ... issued the findings of its 2009 Clinical Trials Risk Map ... pharmaceutical and medical device companies conduct business ...
    ... STAMFORD, Conn., Sept. 17 Cowen Healthcare ... established a Strategic Advisory Board to extend the Firm,s ... The Board will be comprised of industry veterans with ... is expected to supplement Cowen Royalty,s due diligence, opportunity ...
    ... ... pharma, biotech, medical device, and software industries, among others , ... Boston, Massachusetts (Vocus) -- Brown Rudnick, an ... Godward Kronish LLP has joined the Firm,s Boston office. With over 35 years of ...
    Cached Biology Technology:Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 2Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 3Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 4Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 5Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 2Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 3Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 4Veteran Intellectual Property Team Joins Brown Rudnick 2
    (Date:7/11/2014)... relationships with other group members to reduce aggression and ... the strategy for grooming activities shows a certain pattern ... the scientific journal Biology Letters . , Grooming ... practiced without ulterior motives. To be groomed has hygienic ... grooming another individual can provide access to infants, mating ...
    (Date:7/11/2014)... The increased risk of kidney injury related to the ... the mass of HES molecules, according to a report ... the International Anesthesia Research Society (IARS). , The "total ... HES on cultured human renal proximal tubule cells (PTCs), ... colleagues of University Hospital Wrzburg, Austria. Other factorssuch ...
    (Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
    Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
    ... the popular Newscripts page in Chemical & Engineering News ... romance and hauled in a catch that includes fake Viagra ... the bedbug. C&EN is the weekly newsmagazine of the American ... first on a study that checked the authenticity of Viagra ...
    ... Kansas State University professor,s research on breast cancer stem ... recurrence and metastasis -- the major causes of death ... of biochemistry and molecular biophysics, has received a four-year ... at the National Institutes of Health -- to study ...
    ... SAN FRANCISCO February 12, 2013 New findings from ... may predict whether a person is likely to develop age-related ... more than nine million Americans, these genes do not predict ... medications most widely used to treat the "wet" form of ...
    Cached Biology News:Research improving breast cancer treatment by targeting tumor initiating cells 2Research improving breast cancer treatment by targeting tumor initiating cells 3Major clinical trial finds no link between genetic risk factors and 2 top wet AMD treatments 2
    ... Andrew J. Davison and ... • Contents include: information ... viruses, paramyxoviruses, influenza and ... covers analysis of viral ...
    ... U. Desselberger (1995) • This book ... together classical and molecular techniques currently ... infections and analysis of virus-specific antibodies ... are presented covering immunoassays, blotting and ...
    ...
    ... provide rapid and efficient removal of short ... salts from PCR products (Figure 1). The ... Binding Buffer options for fragments >100 bp ... in either single column or 96-well plate ...
    Biology Products: